en · de · es · fr · pt
cardarine-notes.peptides6155.com › Info › Preclinical Findings And Safety Signals — Common Mistakes

Preclinical Findings And Safety Signals — Common Mistakes

By Editorial Desk · published 2025-12-06 · last reviewed 2026-01-27 · Info

LC-MS/MS comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-01-27. Numbers and descriptions here follow the published literature rather than marketing material.

Preclinical Findings and Safety Signals

Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.

Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.

Detection, Stability, and Quality

Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.

Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.

Quality assessment for cardarine samples usually combines identity, purity, and impurity testing. Nuclear magnetic resonance spectroscopy and mass spectrometry can confirm molecular structure, while high-performance liquid chromatography estimates purity. Certificates of analysis from testing laboratories may list these results, but they do not establish safety or legality. In the absence of approved manufacturing, products sold online may contain the wrong compound, variable amounts, or unlisted contaminants. Independent verification is therefore central to analytical work and to interpreting any reported biological activity.

Cardarine at a glance

PropertyValueNotes
Primary targetPPARδ (NR1C2)Nuclear receptor involved in lipid metabolism
Preclinical effectIncreased fatty acid oxidationObserved in rodent studies
Key safety signalTumors in rodents after long-term exposureContributed to halted clinical development
Human trial statusNo approved product; development stoppedLimited short-term metabolic data
Sport regulatory statusProhibited at all timesWADA hormone and metabolic modulators class

Detection, Regulation, and Quality Context

Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.

Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.

Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.

Related pages on this site

Regulatory Status and Detection Context

Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.

Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.

A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.

Supporting material

First Division (level 2) Runners-up: 1996–97 Third Division North / Third Division / League One (level 3) Champions: 1933–34, 1938–39, 1954–55 Runners-up: 1980–81, 2018–19 Play-off winners: 2006, 2016 Fourth Division (level 4) 2nd place promotion: 1967–68 4th place promotion: 1978–79 Cup

He presented the mechanism of the β-lactam development with proton sponge as the stoichiometric base, and also discussed the kinetic analysis of the catalyzed reaction of alkenes with α-imino esters. Lectka has studied the transition-metal catalyzed amide isomerization and peptide folding. He presented the first spectroscopic and crystallographic proof of copper(II)-sodium coordination in tertiary amides and discussed the role of side chain in substituted prolines as a binding site for copper. Lectka's research during his term at Johns Hopkins University also focused on enantioselective halogenation, cooperative asymmetric catalysis, the medicinal chemistry of fluorinated molecules, and studies on asymmetric catalysis on sequentially-linked columns leading to synthesis machines. He conducted research on the chemistry of [C-F-C] fluoronium ions and later reported first spectroscopic evidence for fluoronium ions in a solution. Lectka has also worked on metal-catalyzed aliphatic fluorination and site-selective aliphatic fluorination. Lectka has also established the use of fluorine as a through-space activating substituent for aromatic substitution.

By 1300, Moscow was one of the leading principalities within Vladimir-Suzdal, alongside Tver. On the right bank of the Moskva River—at a distance of eight kilometers (5 mi) from the Kremlin—Daniel founded the first monastery with the wooden church of St. Daniel-Stylite, which is now the Danilov Monastery. Following Daniel's death in 1303, the territory of the principality almost tripled in size, encompassing the entire Moskva River along with its tributaries, which allowed Moscow to become self-sufficient. The principality was also provided with a river network that facilitated trade. Daniel's descendants struggled with the princes of Tver over succession to the grand principality. Yury won recognition as the grand prince from the contemporary Mongol khan in 1318, but Yury lost the title four years later. Ivan I recovered the grand princely throne from Tver after proving himself to be a loyal servant of the khan. Ivan collected tribute for the khan of the Golden Horde from dependent Russian princes, and he used the funds that he acquired to develop Moscow. In addition, the metropolitan of the Russian Church found an ally in Ivan and moved his seat from the nominal capital of Vladimir to Moscow. The foundation of Moscow's first stone church, the Dormition Cathedral, was laid in 1326, and the metropolitan chose to be buried there—an act that confirmed Moscow's status as the spiritual center of Russian Orthodoxy. Masonry building continued in the following years with the construction of additional stone churches.

Sources: en.wikipedia.org

Supporting material

Gene expression genetically low (aceruloplasminemia) Copper levels are low in general Malnutrition/trace metal deficiency in the food source Zinc toxicity, due to induced copper deficiency Copper does not cross the intestinal barrier due to ATP7A deficiency (Menkes disease and Occipital horn syndrome) Delivery of copper into the lumen of the ER-Golgi network is absent in hepatocytes due to absent ATP7B (Wilson's disease)

This policy was spearheaded by Minister of War Winston Churchill. France, Japan and the United States also sent forces to help decide the Russian Civil War in the Whites’ favor. Lenin made peace overtures to Wilson, and the American leader responded by sending diplomat William Bullitt to Moscow. The Allies ultimately rejected the ceasefire terms which Bullitt negotiated, believing that a White victory was imminent. However, the Bolsheviks, operating a unified command from a central location, defeated all the opposition one by one and took full control of Russia, as well as breakaway provinces such as Ukraine, Georgia, Armenia, and Azerbaijan. Bainbridge Colby, the American Secretary of State, in 1920 announced an American policy of refusing to deal with the new regime. Soviet Russia found itself isolated in international diplomacy. Lenin stated that the Soviet Union was surrounded by a "hostile capitalist encirclement" and he viewed diplomacy as a weapon to keep Soviet enemies divided. Lenin set up the Comintern, which called for revolutionary upheavals in capitalist countries. Nevertheless, Communist revolutions failed in Germany, Bavaria, and Hungary and by the mid-1920s Moscow was no longer fomenting revolution.

== History == Evidence that the small intestine controls the release of bile was uncovered as early as 1856, when French physiologist Claude Bernard showed that when dilute acetic acid was applied to the orifice of the bile duct, the duct released bile into the duodenum. In 1903, the French physiologist Émile Wertheimer showed that this reflex was not mediated by the nervous system. In 1904, the French physiologist Charles Fleig showed that the discharge of bile was mediated by a substance that was conveyed by the blood. There remained the possibility that the increased flow of bile in response to the presence of acid in the duodenum might be due to secretin, which had been discovered in 1902. The problem was finally resolved in 1928 by Andrew Conway Ivy and his colleague Eric Oldberg of the Northwestern University Medical School, who found a new hormone that caused contraction of the gall bladder and that they called "cholecystokinin". In 1943, Alan A. Harper and Henry S. Raper of the University of Manchester discovered a hormone that stimulated pancreatic enzyme secretion and that they named "pancreozymin"; however, pancreozymin was subsequently found to be cholecystokinin. Swedish biochemists Johannes Erik Jorpes and Viktor Mutt undertook the monumental task of isolating and purifying porcine cholecystokinin and then determining its amino acid sequence. They finally presented porcine cholecystokinin's amino acid sequence in 1968.

== See also == Crystal structure prediction Dynamical system Memetics Metastability Ostwald's rule of stages Protein folding#Misfolded proteins Prion Protein folding#Energy landscape of protein folding Proteinopathy#Seeded induction Schild's Ladder Self-replicating machine Self-replication Strangelet#Potential propagation

Sources: en.wikipedia.org

Supporting material

== Poppy straw crops == Annual world production of opium and poppy straw, both legal and illegal, is tabulated by the United Nations Office on Drugs and Crime, and reported in its annual World Drug Report. The quantity of poppy straw produced is typically given as "opium equivalents". The 2002 World Drug Report estimate of the total world opium production, including opium equivalents of poppy straw, was 42,600 metric tons (41,900 long tons) in 1906/07 and 12,600 metric tons (12,400 long tons) in 2007. The 2007 production consisted of 8,870 metric tons (8,730 long tons) of illegal opium, 3,420 metric tons (3,370 long tons) of opium equivalent from legal poppy straw, and 300 metric tons (300 long tons) of legal opium. Thus, over 90% of the world production of legal opiates, including medical morphine, is now produced from poppy straw. With the establishment of poppy straw as the source of the majority of natural morphine and other opiates, much of the world production of opium is destined for illicit uses. In 1981 dried capsules being sold for decoration in Sweden were found to have been lanced 2 – 5 times with a tool having 3 to 4 blades and the opium scraped off. The morphine content of these capsules was 0.15 – 0.34%, comparable to domestic Swedish capsules not lanced. In India, poppy straw from lanced capsules had a morphine content of at least 0.2%. These levels of morphine obtained from "exhausted" plants suggests that for producers of licit opium, poppy straw may be a profitable second crop.

== Medical use == Paclitaxel is approved in the UK for ovarian, breast, lung, bladder, prostate, melanoma, esophageal, and other types of solid tumor cancers as well as Kaposi's sarcoma. It is recommended in National Institute for Health and Care Excellence (NICE) guidance of June 2001 for non-small-cell lung cancer in patients unsuitable for curative treatment, and in first-line and second-line treatment of ovarian cancer. In September 2001, NICE recommended paclitaxel for the treatment of advanced breast cancer after the failure of anthracyclic chemotherapy, but that its first-line use should be limited to clinical trials. In September 2006, NICE recommended paclitaxel should not be used in the adjuvant treatment of early node-positive breast cancer. It is approved in the United States for the treatment of breast, pancreatic, ovarian, Kaposi's sarcoma and non-small-cell lung cancers.

== Function == FLAP is necessary for the activation of 5-lipoxygenase and therefore for the production of leukotrienes, 5-hydroxyeicosatetraenoic acid, 5-oxo-eicosatetraenoic acid, and specialized pro-resolving mediators of the lipoxin and resolvin classes. It is an integral protein within the nuclear membrane. FLAP is necessary in synthesis of leukotriene, which are lipid mediators of inflammation that is involved in respiratory and cardiovascular diseases. FLAP functions as a membrane anchor for 5-lipooxygenase and as an amine acid-bind protein. How FLAP activates 5-lipooxygenase is not completely understood, but there is a physical interaction between the two. FLAP structure consists of 4 transmembrane alpha helices, but they are found in trimer forming a barrel. The barrel is about 60 Å high and 36 Å wide.

Sources: en.wikipedia.org

Frequently asked questions

What did animal studies show?

Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.

Has cardarine been tested in humans?

Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.

Does cardarine improve athletic performance in people?

Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.

How is cardarine measured in biological samples?

LC-MS/MS is common, often after sample cleanup. The assay targets GW501516 or its metabolites.

Network